Novo Nordisk Shares Still Have a Long Road Back from 40% Slump
Novo Nordisk A/S investors got a much-needed boost from last week’s trial results for an experimental weight-loss shot. But ...
FDA approves Ozempic to help reduce risk of worsening chronic kidney disease
The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...
New FDA Approval: Ozempic Gets Nod For Kidney Protection In Type 2 Diabetes
The FDA has approved Ozempic to reduce kidney failure risk in people with type 2 diabetes and chronic kidney disease. Studies ...
Novo Nordisk will test CagriSema's long-term efficacy in late-stage trial, clinicaltrials.gov entry shows
Novo Nordisk will begin a new late-stage trial of its experimental next-generation obesity drug CagriSema on Feb. 10, according to a entry.
Contract Pharma15h
FDA Approves Ozempic in Chronic Kidney Disease
The approval is based on results from the Phase III FLOW trial demonstrating Ozempic reduced the risk of severe kidney outcomes by 24% compared to placebo, including kidney failure, reduction in ...
clinicalpainadvisor.com16h
Ozempic Approval Expanded to Include T2D Patients With Chronic Kidney Disease
The FDA has approved Ozempic (semaglutide) to reduce the risk of kidney disease worsening and cardiovascular death in those with T2D and CKD.
Hosted on MSN19h
Ozempic receives FDA nod for treating chronic kidney disease; experts explain how diabetes drug reduces CKD risk
The US Food and Drug Administration (FDA) approval is based on the clinical trials that showed how Ozempic, the diabetes drug ...
Daily21h
FDA approves Semaglutide for renal protection among diabetes patients with CKD
Novo Nordisk has announced that the Food and Drug Administration (FDA) has approved semaglutide (Ozempic) to reduce the risk ...